One of the major clinically challenging types of breast cancer, known as triple-negative breast cancer (TNBC), is negative for hormone receptors (HRs), i.e., estrogen receptors (ER-), progesterone receptors (PR-), and excess human epidermal growth factor receptor 2 (HER2) proteins. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.